Status:
RECRUITING
The Clinical Characteristics, Treatment and Prognosis of Tuberculosis-associated COPD
Lead Sponsor:
Peking University Third Hospital
Collaborating Sponsors:
Peking University Shougang Hospital
The First Affiliated Hospital of Guangzhou Medical University
Conditions:
COPD
Eligibility:
All Genders
35+ years
Brief Summary
Chronic obstructive pulmonary disease (COPD) still imposes a substantial health and economic burden worldwide. Pulmonary tuberculosis has been confirmed as an important risk factor for COPD and this s...
Detailed Description
A nationwide, multicenter, prospective, observational cohort study enrolling consecutive tuberculosis-associated COPD patients (study group) and non-tuberculosis associated COPD patients (control grou...
Eligibility Criteria
Inclusion
- patients who have dyspnea, chronic cough or sputum production and have definite airflow limitation with a post-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) \<0.7;
- in stable condition;
- aged 35 years or older
Exclusion
- bronchiectasis, asthma or any other obstructive pulmonary diseases;
- pneumonia or active tuberculosis;
- severe hepatic or renal insufficiency;
- lung cancer or other advanced malignancies;
- acquired immune deficiency due to HIV or chemotherapy;
- severe trauma, operation or stress status in the past one month;
- severe cognitive dysfunction;
- unwilling to provide informed consent
Key Trial Info
Start Date :
May 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
540 Patients enrolled
Trial Details
Trial ID
NCT06074042
Start Date
May 1 2024
End Date
December 31 2025
Last Update
April 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191